ATP13A3 and neuroblastoma: Targeting ATP13A3, either by AMXT 1501 treatment or by silencing its expression, not only inhibits basal and DFMO‐induced compensatory polyamine uptake and reduces the intracellular polyamine pool, but also abrogates colony formation capacity and growth of neuroblastoma cells while increasing the cells' sensitivity to DFMO.